Who Cannot Take Wegovy for Weight Loss? Understanding the Restrictions and Considerations

Last reviewed: June 26, 2026

Last updated: June 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Two conditions rule Wegovy out absolutely. According to the Wegovy prescribing information, it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy injection or Wegovy tablets. Everything else on the label is a caution, a monitoring requirement, or a combination to avoid — real considerations, but ones a prescriber weighs rather than bright lines. Here is what the label actually separates into which category.

The Two Absolute Contraindications

The thyroid contraindication traces to the boxed warning. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. The label is explicit that it is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent finding has not been determined. The contraindication is a precaution built on an unresolved question, and it extends to family history — not only your own diagnosis.

The hypersensitivity contraindication is narrower but equally firm. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Wegovy. Note that the wording covers the excipients as well as semaglutide itself, and the excipients differ between the injection and the tablets. That is a distinction only a prescriber with your reaction history can apply.

Pregnancy, Planned Pregnancy, and Breastfeeding

The label states plainly that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs that Wegovy be discontinued in pregnant patients using it for weight reduction. Because semaglutide has a long half-life — roughly one week — the label also advises discontinuing it at least two months before a planned pregnancy for patients taking it for cardiovascular risk reduction or weight reduction.

Breastfeeding guidance is presentation-specific. For Wegovy tablets, the label advises that breastfeeding is not recommended, citing the unknown potential for serious adverse reactions in a breastfed infant from accumulation of SNAC, the absorption enhancer used in the oral formulation, and noting that alternative semaglutide formulations without SNAC exist. This is one of several places where the tablet and the injection are not interchangeable.

Conditions That Trigger Caution Rather Than Exclusion

The warnings and precautions section runs to eleven subsections, and several name populations that need closer attention. Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Wegovy. Acute gallbladder disease and acute kidney injury due to volume depletion each carry their own subsection, the latter linked to the fluid losses that can accompany severe nausea, vomiting, or diarrhea.

Two are stated in stronger terms. Wegovy is not recommended in patients with severe gastroparesis. And for patients who also have type 2 diabetes, the label flags diabetic retinopathy complications, noting that rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy and that patients with a history of it should be monitored for progression. The effect of long-term glycemic control with semaglutide on retinopathy complications has not been studied.

Two more affect situations rather than diagnoses. Wegovy has been associated with increases in resting heart rate, with mean increases of 1 to 4 beats per minute observed in injection-treated patients, and the label calls for monitoring heart rate at regular intervals. Pulmonary aspiration during general anesthesia or deep sedation has been reported in patients on GLP-1 receptor agonists undergoing elective procedures, which is why the label instructs patients to inform their healthcare providers of any planned surgery or procedure.

Combinations the Label Advises Against

Under limitations of use, the label states that concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. Stacking is not a shortcut, and it is not something the labeling supports.

Separately, the risk of hypoglycemia is increased when Wegovy is used alongside insulin or an insulin secretagogue such as a sulfonylurea, and the label directs that patients with diabetes have blood glucose monitored before and during treatment. It also notes that use of Wegovy in patients with type 1 diabetes mellitus, or in combination with insulin, has not been evaluated — an absence of data rather than a finding of harm, but an absence that matters.

Where the Injection and the Tablets Diverge

People often assume the two Wegovy formulations are the same drug in a different wrapper. The indications say otherwise. Wegovy injection carries indications for cardiovascular risk reduction, for weight reduction in adults and in pediatric patients aged 12 years and older with obesity as well as adults with overweight plus at least one weight-related comorbid condition, and — under accelerated approval — for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis.

Wegovy tablets carry two: cardiovascular risk reduction and weight reduction in adults. Their safety and effectiveness have not been established in pediatric patients, and the label states they have not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight. If a conversation about eligibility assumes the tablets and the injection cover the same ground, it is starting from the wrong premise.

What Changed on the Label Recently

Labels are living documents, and eligibility discussions age badly. The Wegovy label's revision history shows the Suicidal Behavior and Ideation subsection was removed in February 2026, the severe gastrointestinal adverse reactions subsection was revised in October 2025, and the acute kidney injury subsection in August 2025. The dosage and administration section was revised three times between August 2025 and March 2026, which is when the 7.2 mg once-weekly maximum for Wegovy injection entered the labeling.

The practical consequence is that a list of who cannot take Wegovy assembled two years ago is not the list a prescriber is working from today. The current label on DailyMed is the version that governs, and the person who applies it to your history is your prescriber.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Who is absolutely not allowed to take Wegovy?

The label lists two contraindications. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in patients who have had a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy injection or Wegovy tablets. Every other restriction on the label is a caution or a monitoring requirement rather than an absolute bar.

Can you take Wegovy while pregnant or trying to conceive?

The label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs that Wegovy be discontinued in pregnant patients using it for weight reduction. Because semaglutide has a half-life of roughly one week, the label also advises discontinuing it at least two months before a planned pregnancy for patients taking it for weight reduction or cardiovascular risk reduction.

Does a history of pancreatitis or gallbladder disease disqualify you?

Neither is listed as a contraindication. Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing forms, has been observed with GLP-1 receptor agonists including Wegovy, and acute gallbladder disease has its own warnings subsection. These are matters for your prescriber to weigh against your history, not automatic exclusions. Severe gastroparesis is stated more strongly: Wegovy is not recommended in those patients.

Can Wegovy be combined with another GLP-1 medication?

The label's limitations of use state that concomitant use of Wegovy tablets or Wegovy injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. Separately, using Wegovy alongside insulin or an insulin secretagogue such as a sulfonylurea increases the risk of hypoglycemia, and the label calls for blood glucose monitoring before and during treatment in patients with diabetes.

Are the eligibility rules the same for Wegovy tablets and Wegovy injection?

No. Wegovy injection carries indications for cardiovascular risk reduction, weight reduction in adults and in pediatric patients aged 12 and older with obesity, and, under accelerated approval, noncirrhotic MASH with moderate to advanced fibrosis. Wegovy tablets carry only the first two, have not been established in pediatric patients, and have not been studied for weight reduction in adults with type 2 diabetes.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.